Short Interest in InMed Pharmaceuticals Inc. (NASDAQ:INM) Expands By 188.8%

InMed Pharmaceuticals Inc. (NASDAQ:INM) was the target of a large increase in short interest in October. As of October 31st, there was short interest totalling 115,500 shares, an increase of 188.8% from the October 15th total of 40,000 shares. Based on an average daily trading volume, of 6,410,000 shares, the short-interest ratio is presently 0.0 days.

InMed Pharmaceuticals Stock Up 9.3 %

Shares of NASDAQ:INM opened at $5.08 on Friday. The firm has a market capitalization of $67.82 million, a PE ratio of -3.20 and a beta of 0.36. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.78 and a current ratio of 4.41. InMed Pharmaceuticals has a 52-week low of $2.41 and a 52-week high of $15.70. The firm has a fifty day moving average of $0.25 and a 200 day moving average of $0.26.

InMed Pharmaceuticals (NASDAQ:INM) last posted its quarterly earnings data on Friday, September 27th. The company reported ($0.19) earnings per share (EPS) for the quarter. The firm had revenue of $1.28 million during the quarter. InMed Pharmaceuticals had a negative return on equity of 71.97% and a negative net margin of 166.94%.

About InMed Pharmaceuticals

InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.